4168
the present study is noteworthy. Further investigations for the synthesis of the more complicated and
biologically significant 9-methoxystrobilurin K, L and other analogues are now in progress.
References
1. Zapf, S.; Werle, A.; Anke, T.; Klostermeyer, D.; Steffan, B.; Steglich, W. Angew. Chem., Int. Ed. Engl. 1995, 34, 196–198.
2. (a) Sauter, H.; Steglich, W.; Anke, T. Angew. Chem., Int. Ed. Engl. 1999, 38, 1328–1349. (b) Anke, T.; Steglich, W. In
Biologically Active Molecules: Identification, Characterization and Synthesis; Schlunegger, U. P., Ed.; Springer-Verlag:
Berlin, Heidelberg, 1989; pp. 1–8. (c) Clough, J. M. Natural Products Reports 1993, 10, 565–574.
3. Although another structure was originally proposed for 9-methoxystrobilurin K,1 Blunt and Munro et al. claimed a present
structure 2 in 1997.4 Recently, Anke and Steglich et al. formally revised the structure to 2 by the comparison of s synthetic
benzodioxepin moiety with the degradation product of natural strobilurin K. 5
4. Nicholas, G. M.; Blunt, J. W.; Cole, A. L. J.; Munro, M. H. G. Tetrahedron Lett. 1997, 38, 7465–7468.
5. Hellwig, V.; Dasenbrock, J.; Klostermeyer, D.; Kroiß, S.; Sindlinger, T.; Spiteller, P.; Steffan, B.; Steglich, W.; Engler-Lohr,
M.; Semar, S.; Anke, T. Tetrahedron 1999, 55, 10101–10118.
6. Wood, K. A.; Kau, D. A.; Wrigley, S. K.; Beneyto, R.; Renno, D. V.; Ainsworth, A. M.; Penn, J.; Hill, D.; Killacky, J.;
Depledge, P. J. Nat. Prod. 1996, 59, 646–649.
7. (a) Anke, T.; Schramm, G.; Schwalge, B.; Steffan, B.; Steglich, W. Liebig. Ann. Chem. 1984, 1616–1625. (b) Beautement,
K.; Clough, J. M. Tetrahedron Lett. 1987, 28, 475–478.
8. This compound was purchased from Tokyo Kasei Industries, Inc.
9. (a) Milstein, D.; Stille J. K. J. Am. Chem. Soc. 1978, 100, 3636. (b) Farina, V.; Krishnamurthy, V.; Scott, W. J. Organic
Reactions 1997, 50, 1.
10. The yield of the coupling compound was moderate (61%) when 1.2 eqivalent of vinyl ketone was used, probably due to a
thermal polymerization of vinyl ketone during the Heck reaction.
11. The irradiation condition has not yet been optimized in terms of the light density.
12. Spectral data of synthesized 9-methoxystrobilurin A (1): 1H NMR (CDCl3, 300 MHz) δ 1.91 (s, 3H, H-14), 3.68 (s, 3H,
H-17), 3.72 (s, 3H, H-16), 3.82 (s, 3H, H-15), 6.52 (d, 1H, J=16.0 Hz, H-8), 6.71 (d, 1H, J=16.0 Hz, H-7), 7.20 (m, 1H,
H-3), 7.30 (dd, 2H, J=7.3 Hz, 8.0 Hz, H-2 and H-4), 7.37 (d, 2H, J=7.2 Hz, H-1 and H-5), 7.40 (s, 1H, H-12); 13C NMR
(CDCl3, 75.5 MHz) δ 16.3 (C-14), 51.6 (C-16), 59.5 (C-17), 61.8 (C-15), 110.5 (C-11), 118.8 (C-10), 121.5 (C-8), 126.5
(C-1 C-5), 127.3 (C-3) 127.6 (C-7), 128.5 (C-2 C-4), 137.5 (C-6), 152.6 (C-9) 159.3 (C-12), 167.1 (C-13); EI-MS 288
(M+).
13. Spectral data of synthesized 2,3,9-trimethoxystrobilurin A (11b): 1H NMR (CDCl3, 300 MHz) δ 1.91 (s, 3H, H-14), 3.68
(s, 3H, H-17), 3.72 (s, 3H, H-16), 3.82 (s, 3H, H-15), 3.88 (s, 3H, MeO-Ar), 3.90 (s, 3H, MeO-Ar), 6.37 (d, 1H, J=16.0 Hz,
H-8), 6.66 (d, 1H, J=16.0 Hz, H-7), 6.81 (d, 1H, J=8.3 Hz, H-4), 6.89 (d, 1H, J=1.7 Hz, H-1), 6.96 (dd, 1H, J=1.7, 8.3 Hz,
H-5), 7.40 (s, 1H, H-12); 13C NMR (CDCl3, 75.5 MHz) δ 16.2 (C-14), 51.5 (C-16), 55.9 (C-18 C-19), 59.5 (C-17), 61.8
(C-15), 109.4 (C-4), 110.6 (C-11), 111.1 (C-10), 117.8 (C-10), 119.4 (C-5), 119.7 (C-8) 127.4 (C-7), 130.6 (C-6) 148.6
(C-3), 148.9 (C-2), 152.7 (C-9), 159.3 (C-12), 168.2 (C-13); EI-MS 348 (M+).